File(s) under permanent embargo
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial
journal contribution
posted on 2014-04-01, 00:00 authored by A Ghanizadeh, A Sahraeizadeh, Michael BerkMichael BerkAripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile.
History
Journal
Child Psychiatry & Human DevelopmentVolume
45Issue
2Pagination
185 - 192Publisher
SpringerLocation
New York, NYPublisher DOI
eISSN
1573-3327Language
engPublication classification
C1 Refereed article in a scholarly journal; C Journal articleCopyright notice
2014, SpringerUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC